Glenmark Pharmaceuticals Ltd 2022 SR
The report highlights Glenmark's progress in ESG transformation during FY 2021-22, focusing on innovation in respiratory, oncology, and dermatology. Key achievements include the launch of FabiSpray and Ryaltris-AZ, and a commitment to the Science Based Targets initiative (SBTi). The company aims for carbon neutrality by 2030, water neutrality by 2025, and zero waste to landfill by 2027. Socially, Glenmark impacted over 2.6 million lives through CSR and maintained a diverse workforce with 14.5% women. Governance was strengthened by establishing a dedicated ESG Board Committee.
Company: Glenmark Pharmaceuticals Ltd
Sector: Manufacturing
Country: India
Year: 2022
Type: SR
Pages: 113
Glenmark Pharmaceuticals Ltd
The report highlights Glenmark's progress in ESG transformation during FY 2021-22, focusing on innovation in respiratory, oncology, and dermatology. Key achievements include the launch of FabiSpray and Ryaltris-AZ, and a commitment to the Science Based Targets initiative (SBTi). The company aims for carbon neutrality by 2030, water neutrality by 2025, and zero waste to landfill by 2027. Socially, Glenmark impacted over 2.6 million lives through CSR and maintained a diverse workforce with 14.5% women. Governance was strengthened by establishing a dedicated ESG Board Committee.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2022
Reporting Period
Apr 1, 2021 - Mar 31, 2022
Fiscal Year
2022
Published
Sep 8, 2022
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
Sustainable Development Goals
Other Standards
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Energy Consumption
Renewable Energy
Water Consumption
Total Waste
Women on Board
Women in Management
Workplace Fatalities
Net Zero Target
Employees